Journal of the American Society of Nephrology
2008 JASN IMPACT FACTOR 7.505 HOME   AUTHOR INFO   EDITORIAL BOARD   SUBSCRIBE   FEEDBACK   ALERTS   HELP 
    advanced
CURRENT ISSUE ARCHIVES JASN Express ONLINE SUBMISSION


Published ahead of print on February 8, 2006
J Am Soc Nephrol 17: 707-715, 2006
© 2006 American Society of Nephrology
doi: 10.1681/ASN.2005070698

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
ASN.2005070698v1
17/3/707    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Thurman, J. M.
Right arrow Articles by Holers, V. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Thurman, J. M.
Right arrow Articles by Holers, V. M.

Basic Immunology and Pathology

Treatment with an Inhibitory Monoclonal Antibody to Mouse Factor B Protects Mice from Induction of Apoptosis and Renal Ischemia/Reperfusion Injury

Joshua M. Thurman*, Pamela A. Royer*, Danica Ljubanovic{dagger}, Belda Dursun*, Amanda M. Lenderink*, Charles L. Edelstein* and V. Michael Holers*

* Department of Medicine, University of Colorado Health Sciences Center, Denver, Colorado; and {dagger} Department of Pathology, University Hospital Dubrava, Zagreb, Croatia

Address correspondence to: Dr. Joshua M. Thurman, University of Colorado Health Sciences Center, Division of Renal Diseases and Hypertension, 4200 E. 9th Avenue, B-115, Denver, CO 80262. Phone: 303-315-0171; Fax: 303-315-5540; joshua.thurman{at}uchsc.edu

Received for publication July 8, 2005. Accepted for publication December 10, 2005.

Complement activation in the kidney after ischemia/reperfusion (I/R) seems to occur primarily via the alternative complement pathway. The ability of an inhibitory mAb to mouse factor B, a necessary component of the alternative pathway, to protect mice from ischemic acute renal failure was tested. Treatment with the mAb prevented the deposition of C3b on the tubular epithelium and the generation of systemic C3a after renal I/R. Treated mice had significantly lower increases in serum urea nitrogen and developed significantly less morphologic injury of the kidney after I/R. For gaining insight into potential mechanisms of protection, the activity of caspases within the kidney also was measured, and it was found that caspases-2, -3, and -9 increased in a complement-dependent manner after renal I/R. Apoptotic cells were detected by terminal deoxynucleotidyl transferase catalyzed labeling of DNA fragments, and mice in which the alternative pathway was inhibited demonstrated significantly less apoptosis than control mice. Thus, use of an inhibitory mAb to mouse factor B effectively prevented activation of complement in the kidney after I/R and protected the mice from necrotic and apoptotic injury of the tubules.




This article has been cited by other articles:


Home page
Am. J. Pathol.Home page
X. Zheng, X. Zhang, B. Feng, H. Sun, M. Suzuki, T. Ichim, N. Kubo, A. Wong, L. R. Min, M. E. Budohn, et al.
Gene Silencing of Complement C5a Receptor Using siRNA for Preventing Ischemia/Reperfusion Injury
Am. J. Pathol., October 1, 2008; 173(4): 973 - 980.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Renal Physiol.Home page
A. M. Lenderink, K. Liegel, D. Ljubanovic, K. E. Coleman, G. S. Gilkeson, V. M. Holers, and J. M. Thurman
The alternative pathway of complement is activated in the glomeruli and tubulointerstitium of mice with adriamycin nephropathy
Am J Physiol Renal Physiol, August 1, 2007; 293(2): F555 - F564.
[Abstract] [Full Text] [PDF]


Home page
J. Am. Soc. Nephrol.Home page
L. Bao, Y. Wang, A. Chang, A. W. Minto, J. Zhou, H. Kang, M. Haas, and R. J. Quigg
Unrestricted C3 Activation Occurs in Crry-Deficient Kidneys and Rapidly Leads to Chronic Renal Failure
J. Am. Soc. Nephrol., March 1, 2007; 18(3): 811 - 822.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
J. M. Thurman, A. M. Lenderink, P. A. Royer, K. E. Coleman, J. Zhou, J. D. Lambris, R. A. Nemenoff, R. J. Quigg, and V. M. Holers
C3a Is Required for the Production of CXC Chemokines by Tubular Epithelial Cells after Renal Ishemia/Reperfusion
J. Immunol., February 1, 2007; 178(3): 1819 - 1828.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
D. Spitzer, X. Wu, X. Ma, L. Xu, K. P. Ponder, and J. P. Atkinson
Cutting Edge: Treatment of Complement Regulatory Protein Deficiency by Retroviral In Vivo Gene Therapy
J. Immunol., October 15, 2006; 177(8): 4953 - 4956.
[Abstract] [Full Text] [PDF]


Home page
Nephrol Dial TransplantHome page
M. Nangaku
A Crry for polar shedding
Nephrol. Dial. Transplant., July 1, 2006; 21(7): 1773 - 1775.
[Full Text] [PDF]




HOME CURRENT ISSUE ARCHIVES JASN Express ONLINE SUBMISSION AUTHOR INFO
EDITORIAL BOARD SUBSCRIBE FEEDBACK ALERTS HELP